86541-78-8
Chemical Structure
Benazeprilat
Synonym(s): CGS 14831
- CAS No.: 86541-78-8
- Formula:C22H24N2O5
- Molecular Weight:396.44
IUPAC Name: (S)-2-(((S)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)amino)-4-phenylbutanoic acid
InChIKey: MADRIHWFJGRSBP-ROUUACIJSA-N
SMILES: O=C1[C@H](CCC2=C(C=CC=C2)N1CC(O)=O)N([C@@H](CCC3=CC=CC=C3)C(O)=O)[H]
Biological Activity: Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Benazeprilat | 99.54% | Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Benazeprilat (Standard) | ≥98% | Benazeprilat (Standard) is the analytical standard of Benazeprilat. This product is intended for research and analytical applications. Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Benazeprilat-d5 | Benazeprilat-d5 is the deuterium labeled Benazeprilat. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Barrios V, Antihypertensive and organ-protective effects of benazepril. Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1653-71. [Content Brief]
- [2]. Bazil MK, Hemodynamic effects of amlodipine and benazeprilat in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993 Mar;21(3):405-11. [Content Brief]
- [3]. Mochel JP, Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs. J Vet Pharmacol Ther. 2013 Apr;36(2):174-80. [Content Brief]
